NLS Biotech Business

Evaxion Biotech has entered into an option and license agreement with MSD for two preclinical vaccine candidates.

The company has received a substantial investment from Kempestiftelserna.

Oncopeptides has announced that it has signed an exclusive license and supply agreement with SCBIO, a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea.

The company has recently raised SEK 10 million in directed issue for a novel obesity-related study. The aim is to study drug tolerance and the effects of the company’s molecule on obesity. The Phase-2a-study will be conducted over the next year and the capital raised will support the study with the objective to assess the […]

IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project. “The […]

The European Commission has granted Orphan Medicinal Product Designation (OMPD) to the company’s lead drug candidate CS1 in the rare disease Pulmonary Arterial Hypertension (PAH). “This designation offers significant advantages, including a 10-year market exclusivity period post-authorization and various benefits during the development process, facilitating our efforts to bring CS1 to patients with PAH in […]